Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine, Norwegian University of Science and Technology, University Hospital, Trondheim, Norway.
Pathol Res Pract. 2010 Dec 15;206(12):810-5. doi: 10.1016/j.prp.2010.09.002. Epub 2010 Oct 15.
Histology alone does not always predict the clinical outcome of human meningiomas. Determination of proliferative activity has therefore become an important diagnostic and prognostic tool to identify more aggressive meningiomas, and the Ki-67/MIB-1 monoclonal antibody has become widely used. The aim of this study was to assess the prognostic value of the Ki-67/MIB-1 labeling index (LI) in human meningiomas by a search in the literature. In PubMed/Medline databases, 53 articles were found, and they all showed positive correlations between Ki-67/MIB-1 LI and histological malignancy grade. The average mean labeling indices were 3%, 8%, and 17% for grade I-III meningiomas, respectively. There was, however, considerable overlap of indices between the malignancy groups. Concerning recurrence, meningiomas with a labeling index beyond 4% may indicate an increased relapse rate. Consequently, Ki-67/MIB-1 LI represents a useful predictor of tumor grade and risk of recurrence, however, it must be interpreted cautiously in the individual tumor.
单纯的组织学并不能总是预测人类脑膜瘤的临床结果。因此，确定增殖活性已成为识别侵袭性更强的脑膜瘤的重要诊断和预后工具，Ki-67/MIB-1 单克隆抗体已被广泛应用。本研究旨在通过文献检索评估 Ki-67/MIB-1 标记指数 (LI) 在人类脑膜瘤中的预后价值。在 PubMed/Medline 数据库中，共发现 53 篇文章，均显示 Ki-67/MIB-1 LI 与组织学恶性程度分级之间存在正相关。I-III 级脑膜瘤的平均标记指数分别为 3%、8%和 17%。然而，各恶性肿瘤组之间存在相当大的指数重叠。关于复发，标记指数超过 4%的脑膜瘤可能预示着复发率的增加。因此，Ki-67/MIB-1 LI 是肿瘤分级和复发风险的有用预测指标，但在个别肿瘤中必须谨慎解读。
